Rosuvastatin Affecting Aortic Valve Endothelium

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Recent studies support the hypothesis that aortic stenosis (AS) develops due to atherosclerosis affecting the aortic valve endothelium. The study's aim was to assess Rosuvastatin on the hemodynamic progression and inflammatory markers of AS by treating low-density lipoprotein (LDL) in patients with AS according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) guidelines for one year.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hospital Pedro Hispano
• Collaborator: Northwestern University
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Asymptomatic AS

• Normal ejection fraction

• Elevated LDL >130 mg/dl

Exclusion Criteria:

• Echocardiographic evidence of rheumatic mitral valve disease,

• Previous statin therapy,

• Congenital heart disease (bicuspid aortic valve),

• Subaortic obstruction,

• Creatinine ≥ 2,0 mg/dl (to avoid the potential confounder of an elevated serum [CaP04]),

• Evidence of liver disease,

• Greater than mild aortic regurgitation and previous aortic valve surgery